A best-in-class global molecular diagnostic platform to democratize point of care, thus contributing to the prevention of infectious disease transmission and better health for the citizens of the world.
RNADD is developing a very low-cost molecular diagnostic testing platform for point-of-care diagnosis of infectious diseases to disrupt and democratize molecular testing. Our strategy is to leverage our proprietary Electrochemical and Antisense Oligonucleotide (ASO) molecular testing platform across multiple infectious disease categories including Women’s Health, Respiratory Diseases (Covid-19, Flu A, RSV, Strep A), Sexually Transmitted Infections, and future Pandemics, etc.
LEARN MOREOur POC molecular diagnostic platform, based on our novel and proprietary ASO and electrochemical biosensor technology, provides multiplexed results in 5-minutes. We are developing several multiplexed panels for multiple Infectious Diseases.
LEARN MOREMike C. Kaufmann recently joined the Board of Directors of RNA Disease Diagnostics, Inc. (RNADD). Mike is a former Fortune 15 CEO and CFO, and an active advocate and executive speaker on leadership and diversity, equity, and inclusion (DE&I).
Read MoreRead MoreRNA Disease Diagnostics, Inc. (“RNADD” or the “Company”), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care (“POC”) and home-use infectious disease detection, announced today the appointments of its Chief Scientific Advisor, Professor Dipanjan Pan, M.S., Ph.D., and its President, John W. Erickson, Jr., to the Company’s Board of Directors.
Read MoreRead More